Efficacy and Safety of Lovastatin in Adolescent Males With Heterozygous Familial Hypercholesterolemia

Abstract

This study in adolescent boys with HeFH confirmed the LDL-C-reducing effectiveness of lovastatin. Comprehensive clinical and biochemical data on growth, hormonal, and nutritional status indicated no significant differences between lovastatin and placebo over 48 weeks, although further study is required.